Boehringer's survodutide, a GLP-1 drug that works two ways to help control weight and blood sugar, passed a major late-stage trial (Phase 3). The results show the drug works well and may move toward approval.

• •Boehringer's survodutide passed a Phase 3 trial
• •Survodutide is a dual GLP-1 agonist for weight and blood sugar
• •Trial results may support a path to approval

• •Boehringer's obesity drug showed 16.6% weight loss
• •More data needed before clearer picture emerges

Boehringer's dual agonist drug (a weight-loss medicine that works in two ways) helped people lose up to 16.6% of their body weight in testing. This is an early result from the company's obesity drug program.

• •Boehringer's dual agonist drug led to up to 16.6% weight loss in a trial
• •The drug works on two targets at once
• •Early-stage result from Boehringer's obesity program

Boehringer Ingelheim's experimental two-in-one weight-loss injection passed a late-stage trial (Phase 3), meaning it met the main goal being tested. The company is moving toward asking regulators to approve the drug.

• •Boehringer's dual-acting obesity injection met its main goal in a Phase 3 trial
• •Company plans to seek regulatory approval

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in Phase 3 testing that look more like Novo Nordisk's Wegovy than expected. The finding matters because it helps doctors and investors understand how well the new drug works compared to existing weight-loss medicines.

• •Boehringer and Zealand reported Phase 3 results for their obesity drug
• •Results looked more similar to Novo's Wegovy than expected

A drug made by Boehringer and Zealand Pharma helped patients lose 16.6% of their body weight in a late-stage trial. This is a major test before the companies can ask the FDA to approve the drug.

• •Boehringer-Zealand drug led to 16.6% weight loss in a late-stage trial
• •Result is a key step before seeking FDA approval

Boehringer Ingelheim's dual agonist drug (a new type of weight-loss medicine) showed patients lost 16.6% of their body weight in a Phase 3 trial (a large test to prove the drug works). The company shared results but did not answer some important questions about safety and how well the drug compares to other weight-loss drugs.

• •Boehringer's dual agonist hit 16.6% weight loss in a Phase 3 trial
• •The drug is a dual agonist (works on two targets at once)
• •Boehringer left key safety and comparison questions unanswered

Boehringer Ingelheim's survodutide, a dual-action weight-loss drug, helped people lose 16.6% of their body weight in a Phase 3 trial (a large final test before approval). The drug also improved other health markers related to weight and metabolism.

• •Survodutide hit 16.6% weight loss in a Phase 3 trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial enrolled people with obesity or overweight

• •Boehringer Ingelheim is developing a glucagon/GLP-1 dual agonist peptide